The word “response” can conceal several different measurements. This historical combination trial illustrates why an evidence summary must specify both the test and the time point. Primary study
What was reported
The randomized study included 109 participants across thymosin plus interferon, interferon plus placebo, and double-placebo groups. It reported a favorable end-of-treatment biochemical comparison for the combination against interferon. Viral-RNA clearance was reported separately. Sustained biochemical response was less frequent than the end-of-treatment response and should not be described as sustained virological response. Primary report
Our appraisal: label each result before comparing it
Start with the biological measure. Normalization of a liver enzyme is a biochemical endpoint. Undetectable viral RNA is a virological endpoint. They may be associated, but a favorable result for one does not automatically establish the other.
Next identify when it was measured. An on-treatment or end-of-treatment observation cannot establish persistence after therapy ends. A summary that drops the timing makes a temporary response sound durable.
The comparison itself is the third requirement. A significant change within the combination group is not necessarily a significant difference between the combination and another group. That distinction matters whenever one arm reaches a threshold and another does not. The actual between-group test, rather than the contrast between two significance labels, answers the comparative question.
Finally, a combination result applies to that combination. It does not show what thymosin would achieve alone, and it does not establish interchangeability among interferon regimens or newer treatments.
This paper is best read as a historical controlled experiment with multiple endpoint definitions. Its positive biochemical finding should remain visible alongside the limits on durability and virological interpretation. It should not be converted into a contemporary treatment algorithm.
Frequently asked questions
Was there a placebo comparison?
Yes.
Was thymosin combined with interferon?
Yes, in one study arm.
Was a favorable biochemical result reported?
Yes, at the end of treatment.
Is ALT normalization identical to viral clearance?
No.
Is sustained biochemical response the same as sustained virological response?
No.
Does a within-group change prove comparative superiority?
No.
Does this establish thymosin monotherapy efficacy?
No.